Citadel Advisors
BRTX icon

Citadel Advisors’s BioRestorative Therapies BRTX Stock Holding History

Citadel Advisors’s Portfolio BRTX Stock Details BRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$103K Buy
13,665
+1,735
+15% +$10.1K ﹤0.01% 12684
2026
Q1 		$64.9K Buy
11,930
+10,470
+717% +$134K ﹤0.01% 12291
2025
Q4 		$34.2K Sell
1,460
-3,851
-73% -$103K ﹤0.01% 12184
2025
Q3 		$152K Buy
+5,311
New +$164K ﹤0.01% 11525
2025
Q1 		– Sell
-1,074
Closed -$30.7K – 14519
2024
Q4 		$30.7K Buy
+1,074
New +$33.2K ﹤0.01% 12858

Other funds holding BRTX

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
HRT Financial
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
XTX Topco
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.2B AUM 26.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
KFGK
Keystone Financial Group (Kentucky) Lexington, Kentucky $1.69B AUM 40.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Citadel Advisors's BRTX Position: Q2 2026 in Review

Citadel Advisors increased its BioRestorative Therapies (BRTX) stake by 15% in Q2 2026, buying an estimated $10.1K and bringing the position to 13,665 shares worth $103K. The position accounts for ﹤0.01% of the portfolio, ranked #12684.

Citadel Advisors first reported a position in BRTX in Q4 2024 and has held it in 5 quarters since. The position peaked at $152K in Q3 2025. 18 funds tracked by Wall St. Rank hold BRTX as of Q2 2026.

  • Citadel Advisors held 13,665 shares of BioRestorative Therapies worth $103K as of Q2 2026.
  • Citadel Advisors bought 1,735 BioRestorative Therapies shares in Q2 2026, an estimated $10.1K.
  • BioRestorative Therapies made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12684 holding.
  • Citadel Advisors first reported a position in BioRestorative Therapies in Q4 2024 and has held it in 5 quarters since.
  • Citadel Advisors's BioRestorative Therapies position peaked at $152K in Q3 2025.
  • 18 funds tracked by Wall St. Rank held BioRestorative Therapies as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.